Artificial Intelligence is helpful in detecting pancreatic cancer - Video
|
Overview
An artificial intelligence (AI) tool is highly effective at detecting pancreatic cancer on CT, according to a study published in Radiology, a journal of the Radiological Society of North America (RSNA).
Pancreatic cancer has the lowest five-year survival rate among cancers. It is projected to become the second leading cause of cancer death in the United States by 2030. Early detection is the best way to improve the dismal outlook, as prognosis worsens significantly once the tumor grows beyond 2 centimeters.
CT is the key imaging method for detection of pancreatic cancer, but it misses about 40% of tumors under 2 centimeters. There is an urgent need for an effective tool to help radiologists in improving pancreatic cancer detection.
Researchers in Taiwan have been studying a computer-aided detection (CAD) tool that uses a type of AI called deep learning to detect pancreatic cancer. They previously showed that the tool could accurately distinguish pancreatic cancer from noncancerous pancreas. However, thatm study relied on radiologists manually identifying the pancreas on imaging—a labor-intensive, process known as segmentation. In the new study, the AI tool identified the pancreas automatically. This is an important advance considering that the pancreas borders multiple organs and structures and varies widely in shape and size.
The researchers developed the tool with an internal test set consisting of 546 patients with pancreatic cancer and 733 control participants. The tool achieved 90% sensitivity and 96% specificity in the internal test set.
Validation followed with a set of 1,473 individual CT exams from institutions throughout Taiwan. The tool achieved 90% sensitivity and 93% specificity in distinguishing pancreatic cancer from controls in that set. Sensitivity for detecting pancreatic cancers less than 2 centimeters was 75%.
Reference:
Weichung Wang et al,Pancreatic Cancer Detection on CT Scans with Deep Learning: AnNationwide Population-based Study,Radiology
Speakers
Isra Zaman
B.Sc Life Sciences, M.Sc Biotechnology, B.Ed
Isra Zaman is a Life Science graduate from Daulat Ram College, Delhi University, and a postgraduate in Biotechnology from Amity University. She has a flair for writing, and her roles at Medicaldialogues include that of a Sr. content writer and a medical correspondent. Her news pieces cover recent discoveries and updates from the health and medicine sector. She can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751